Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry

被引:95
作者
Kovalova, Lubomira [1 ,2 ]
McArdell, Christa S. [1 ]
Hollender, Juliane [1 ]
机构
[1] Eawag, Swiss Fed Inst Aquat Sci & Technol, CH-8600 Dubendorf, Switzerland
[2] Rhein Westfal TH Aachen, Inst Hyg & Environm Hlth, D-52072 Aachen, Germany
关键词
Cytostatics; HILIC; Pharmaceuticals; Hospital wastewater; Isobaric interferences; PERFORMANCE LIQUID-CHROMATOGRAPHY; SOLID-PHASE EXTRACTION; CLINICAL PHARMACOKINETICS; CYTOSINE-ARABINOSIDE; URACIL ARABINOSIDE; SILICA COLUMNS; MOUSE PLASMA; 5-FLUOROURACIL; CYTARABINE; GEMCITABINE;
D O I
10.1016/j.chroma.2008.12.028
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A method for solid phase extraction and HPLC-MS/MS of the cytostatics 5-fluorouracil, cytarabine, and gemcitabine and human metabolites uracil 1-beta-D-arabinofuranoside and 2',2'-difluorodeoxyuridine in wastewater was established. Wastewater samples from a Swiss hospital were analyzed for 5-fluorouracil, gemcitabine and 2',2'-difluorodeoxyuridine. The limits of quantification were 5.0, 0.9, and 9.0 ng/L and the maximum concentrations detected were 27, 38, and 840 ng/L, respectively. Along with the method development, retention mechanisms on the hydrophilic interaction chromatography (HILIC) stationary phase were studied. Both partitioning and adsorption play a role in the retention on the tested sulfoalkylbetaine modified silica HILIC column material. The contribution of these two processes is changing over the 1.6-40% range water in the mobile phase. Although the specific break point is difficult to determine, adsorption becomes more significant as the fraction of water in the mobile phase decreases below approximately 16%. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:1100 / 1108
页数:9
相关论文
共 32 条
[1]   A PHASE-I CLINICAL, PLASMA, AND CELLULAR PHARMACOLOGY STUDY OF GEMCITABINE [J].
ABBRUZZESE, JL ;
GRUNEWALD, R ;
WEEKS, EA ;
GRAVEL, D ;
ADAMS, T ;
NOWAK, B ;
MINEISHI, S ;
TARASSOFF, P ;
SATTERLEE, W ;
RABER, MN ;
PLUNKETT, W .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) :491-498
[2]   HYDROPHILIC-INTERACTION CHROMATOGRAPHY FOR THE SEPARATION OF PEPTIDES, NUCLEIC-ACIDS AND OTHER POLAR COMPOUNDS [J].
ALPERT, AJ .
JOURNAL OF CHROMATOGRAPHY, 1990, 499 :177-196
[3]   Pharmaceuticals and personal care products in the environment: Agents of subtle change? [J].
Daughton, CG ;
Ternes, TA .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1999, 107 :907-938
[4]   High performance liquid chromatographic determination of some co-administered anticancer drugs in pharmaceutical preparations and in spiked human plasma [J].
Fahmy, OT ;
Korany, MA ;
Maher, HM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 34 (05) :1099-1107
[5]   Measurement of surface contamination from nucleoside analogue antineoplastic drugs by high-performance liquid chromatography in occupational hygiene studies of oncologic hospital departments [J].
Floridia, L ;
Pietropaolo, AM ;
Tavazzani, M ;
Rubino, FM ;
Colombi, A .
JOURNAL OF CHROMATOGRAPHY B, 1999, 724 (02) :325-334
[6]   New hydrophilic materials for solid-phase extraction [J].
Fontanals, N ;
Marcé, RM ;
Borrull, F .
TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2005, 24 (05) :394-406
[7]   VALIDATED ASSAYS FOR THE DETERMINATION OF GEMCITABINE IN HUMAN PLASMA AND URINE USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION [J].
FREEMAN, KB ;
ANLIKER, S ;
HAMILTON, M ;
OSBORNE, D ;
DHAHIR, PH ;
NELSON, R ;
ALLERHEILIGEN, SRB .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 665 (01) :171-181
[8]  
Grumbach ES, 2004, LC GC N AM, V22, P1010
[9]   Clinical pharmacokinetics of cytarabine formulations [J].
Hamada, A ;
Kawaguchi, T ;
Nakano, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (10) :705-718
[10]  
HEGGIE GD, 1987, CANCER RES, V47, P2203